Healthmed Services Ltd. (HEME) 股价，以美元计价

The Company has acquired the rights from Dr. Henry J. Smith to an improved Donor Organ Transport System (Patent Pending). By reconditioning the donor organ such as the heart, kidney or liver and extending the period of time for transport, it will be possible to improve the success rates of transplants. Also, by having a device that can maintain the organ for an extended period in vitro, it will be possible to test drugs on isolated organs in vitro before starting clinical trials on patients. The Company has made significant progress in its research program and has a working model of a portable organ transport device. Initial research studies have been completed showing that isolated donor organs could be kept alive for an extended period of time using the organ transport system developed. It represents strong possibilities to be the foundation for an enterprise highly profitable to the Company and its shareholders. A merger has been filed with Diabetes Reference Services Inc. to absorb their proprietary technology into the Company. Its business model is to distribute diabetes test kits through retail outlets and online, enabling consumers in a totally confidential manner to predict their propensity to contract diabetes based on testing their saliva to detect certain significant proteins that may be present. Results are available online only to purchasers though confidential codes provided in their kits, without revealing any users' identities to anyone but the purchaser.